XBiotech
XBIT
56 hedge funds and large institutions have $18.9M invested in XBiotech in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 21 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
2.21% less ownership
Funds ownership: 13.25% → 11.04% (-2.2%)
13% less funds holding
Funds holding: 64 → 56 (-8)
33% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 21
46% less capital invested
Capital invested by funds: $34.9M → $18.9M (-$15.9M)
70% less call options, than puts
Call options by funds: $7K | Put options by funds: $23K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.8M |
| 2 |
Morgan Stanley
New York
|
+$1.11M |
| 3 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$923K |
| 4 |
Renaissance Technologies
New York
|
+$529K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$473K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.21M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.79M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$977K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$764K |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$763K |
XBIT Hedge Fund Activity: Q2 2022 in Review
56 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q2 2022, worth a combined $18.9M — down 46% from $34.9M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of XBIT and 14 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 17 added.
The largest buyer was Millennium Management, adding an estimated $1.8M. The largest seller was BlackRock, cutting an estimated $5.21M.
- 56 institutional investors held XBiotech (XBIT) as of Q2 2022, down from 64 in Q1 2022.
- Funds reported $18.9M of XBiotech stock for Q2 2022, down 46% quarter-over-quarter.
- 14 funds opened new XBiotech positions in Q2 2022 and 21 closed out, a net change of -7 holders.
- The largest XBiotech buyer in Q2 2022 was Millennium Management, an estimated $1.8M added.
- The largest XBiotech seller in Q2 2022 was BlackRock, an estimated $5.21M sold.
Based on aggregated 13F filings for Q2 2022.